PEPTIDES FOR DRY EYE DISEASEDisclosed are ophthalmic compositions, methods for using the compositions and kits comprising the compositions for treating dry eye in a subject in need thereof. The composition comprises at least one peptide that is an inhibitor of trans-endothelial migration, an analogue, variant, derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient for treating dry eye and ocular diseases of inflammation.A composition comprising one or more peptides comprising the peptides selected from the group consisting of H-Ser-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu- Glu-Arg-NH2 (SEQ ID NO:1 ), H-DSer-Val-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn- NMeGlu-Glu-Orn-NH2 (SEQ ID NO:2), H-Hyp-Val-Thr-NMeGlu-Gln-Gly-Ala-Glu-Leu- Hyp-DAsn-Glu-Glu-Aha-NH2 (SEQ ID NO:3), H-Ser-Val-Thr-Glu-Gln-Gly-Ala-Glu- Leu-Ser-Asn-Glu-Glu-NH2 (SEQ ID NO:4), H-DSer-Val-AlloThr-Glu-Gln-Gly-Ala-Glu- Nle-Ser-Asn-NMeGlu-GluOMe-NH2 (SEQ ID NO:5), H-Val-Thr-Glu-Gln-Gly-Ala-Glu- Leu-Ser-Asn-Glu-Glu-Arg-NH2 (SEQ ID NO:6), H-Nva-AlloThr-Glu-Gln-Gly-Ala-Glu- Nle-Ser-Asn-NMeGlu-Glu-Orn-NH2 (SEQ ID NO:7), H-Val-Thr-Glu-Gln-Gly-Ala-Glu- Leu-Ser-Asn-Glu-Glu-NH2 (SEQ ID NO:8), H-Nva-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle- Ser-Asn-NMeGlu-GluOMe-NH2 (SEQ ID NO:9), H-Chex-Thr-NMeGlu-Gln-Gly-Ala- Glu-Leu-Hyp-DAsn-Glu-DGIn-NH2 (SEQ ID NO:10), H-Val-Thr-Glu-Gln-Gly-Ala-Glu- Leu-Ser-Asn-Glu-NH2 (SEQ ID NO:1 1 ), H-Nva-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser- Asn-NMeGlu-NH2 (SEQ ID NO:12), H-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu- NH2 (SEQ ID NO:13), H-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-GluOMe- NH2 (SEQ ID NO:14), H-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-NH2 (SEQ ID NO:15), H-AlloThr-Glu-Gln-Nva-Ala-Glu-Nle-Ser-Asn-NMeGlu-NH2 (SEQ ID NO:16), H-DSer-Glu-Gln-Gly-Ala-Glu-Leu-DSer-DAsn-DGIn-NH2 (SEQ ID NO:17), H-Ser-Val- Thr-Glu-Gln-Gly-Ala-Glu-Leu-NH2 (SEQ ID NO:18), H-DSer-Val-Thr-Glu-Gln-Nva- Ala-Glu-Nle-NH2 (SEQ ID NO:19), H-Hyp-Val-Thr-Glu-Gln-Gly-pAla-Glu-Aha-NH2 (SEQ ID NO:20), H-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-NH2 (SEQ ID NO:21 ), H- Nva-Thr-Glu-Gln-Nva-Ala-Glu-Leu-DSer-NH2 (SEQ ID NO:22), H-Chex-Thr-Glu-Gln- Gly-pAla-Glu-Leu-Hyp-NH2 (SEQ ID NO:23), H-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser- Asn-NH2 (SEQ ID NO:24), H-AlloThr-Glu-Gln-Nva-Ala-Glu-Leu-Ser-DAsn-NH2 (SEQ ID NO:25), H-DSer-Glu-Gln-Gly-pAla-Glu-Leu-Ser-DGIn-NH2 (SEQ ID NO:26), H- Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-NH2 (SEQ ID NO:27), H-NMeGlu-Gln-Gly-Ala- Glu-Nle-Ser-Asn-NMeGlu-NH2 (SEQ ID NO:28), H-lsoGln-Gln-Gly-pAla-Glu-Leu-Ser- Asn-GluOMe-NH2 (SEQ ID NO:29), H-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-NH2 (SEQ ID NO:30), H-DAsn-Gly-Ala-Glu-Nle-Ser-Asn-Glu-NMeGlu-NH2 (SEQ ID NO:31 ), H-lsoGln-Gly-pAla-Glu-Leu-Ser-Asn-Glu-GluOMe-NH2 (SEQ ID NO:32), H- Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-Arg-NH2 (SEQ ID NO:33), H-Nva-Ala-Glu-Nle-Ser- Asn-Glu-Glu-Orn-NH2 (SEQ ID NO:34), and H-pAla-Ala-Glu-Leu-DSer-Asn-Glu-Glu- NMeArg-NH2 (SEQ ID NO:35), an analogue thereof, a variant thereof, and a derivative thereof.
안구 건조증 질환을 위한 펩티드안구 건조증의 치료를 필요로 하는 대상체에서 안구 건조증을 치료하기 위한 안과용 조성물, 상기 조성물을 사용하는 방법, 및 상기 조성물을 포함하는 키트가 개시된다. 조성물은 안구 건조증 및 안구 염증 질환을 치료하기 위해 경내피 이동의 억제제인 적어도 1종의 펩티드, 그의 유사체, 변이체, 유도체, 또는 제약상 허용되는 염, 및 제약상 허용되는 부형제를 포함한다.H-Ser-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-Arg-NH2 (서열식별번호: 1), H-DSer-Val-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-Glu-Orn-NH2 (서열식별번호: 2), H-Hyp-Val-Thr-NMeGlu-Gln-Gly-Ala-Glu-Leu-Hyp-DAsn-Glu-Glu-Aha-NH2 (서열식별번호: 3), H-Ser-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-NH2 (서열식별번호: 4), H-DSer-Val-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-GluOMe-NH2 (서열식별번호: 5), H-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-Arg-NH2 (서열식별번호: 6), H-Nva-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-Glu-Orn-NH2 (서열식별번호: 7), H-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-NH2 (서열식별번호: 8), H-Nva-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-GluOMe-NH2 (서열식별번호: 9), H-Chex-Thr-NMeGlu-Gln-Gly-Ala-Glu-Leu-Hyp-DAsn-Glu-DGln-NH2 (서열식별번호: 10), H-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-NH2 (서열식별번호: 11), H-Nva-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-NH2 (서열식별번호: 12), H-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-NH2 (서열식별번호: 13), H-AlloThr-Glu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-GluOMe-NH2 (서열식별번호: 14), H-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-NH2 (서열식별번호: 15), H-AlloThr-Glu-Gln-Nva-Ala-Glu-Nle-Ser-Asn-NMeGlu-NH2 (서열식별번호: 16), H-DSer-Glu-Gln-Gly-Ala-Glu-Leu-DSer-DAsn-DGln-NH2 (서열식별번호: 17), H-Ser-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-NH2 (서열식별번호: 18), H-DSer-Val-Thr-Glu-Gln-Nva-Ala-Glu-Nle-NH2 (서열식별번호: 19), H-Hyp-Val-Thr-Glu-Gln-Gly-βAla-Glu-Aha-NH2 (서열식별번호: 20), H-Val-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-NH2 (서열식별번호: 21), H-Nva-Thr-Glu-Gln-Nva-Ala-Glu-Leu-DSer-NH2 (서열식별번호: 22), H-Chex-Thr-Glu-Gln-Gly-βAla-Glu-Leu-Hyp-NH2 (서열식별번호: 23), H-Thr-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-NH2 (서열식별번호: 24), H-AlloThr-Glu-Gln-Nva-Ala-Glu-Leu-Ser-DAsn-NH2 (서열식별번호: 25), H-DSer-Glu-Gln-Gly-βAla-Glu-Leu-Ser-DGln-NH2 (서열식별번호: 26), H-Glu-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-NH2 (서열식별번호: 27), H-NMeGlu-Gln-Gly-Ala-Glu-Nle-Ser-Asn-NMeGlu-NH2 (서열식별번호: 28), H-IsoGln-Gln-Gly-βAla-Glu-Leu-Ser-Asn-GluOMe-NH2 (서열식별번호: 29), H-Gln-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-NH2 (서열식별번호: 30), H-DAsn-Gly-Ala-Glu-Nle-Ser-Asn-Glu-NMeGlu-NH2 (서열식별번호: 31), H-IsoGln-Gly-βAla-Glu-Leu-Ser-Asn-Glu-GluOMe-NH2 (서열식별번호: 32), H-Gly-Ala-Glu-Leu-Ser-Asn-Glu-Glu-Arg-NH2 (서열식별번호: 33), H-Nva-Ala-Glu-Nle-Ser-Asn-Glu-Glu-Orn-NH2 (서열식별번호: 34), 및 H-βAla-Ala-Glu-Leu-DSer-Asn-Glu-Glu-NMeArg-NH2 (서열식별번호: 35), 그의 유사체, 그의 변이체, 및 그의 유도체로 이루어진 군으로부터 선택된 펩티드를 포함하는 1종 이상의 펩티드를 포함하는 조성물.